Group 1 - The core point of the news is the performance and financial metrics of Aopumai Biotechnology Co., Ltd., which saw a stock price increase of 5.03% to 60.60 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Aopumai was established on November 27, 2013, and went public on September 2, 2022, focusing on cell culture products and services [1] - The company's revenue composition is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1] Group 2 - According to data, Aopumai is a significant holding in the Guangfa Balanced Growth Mixed A Fund, which held 1.5283 million shares, accounting for 2.87% of the fund's net value, ranking as the ninth largest holding [2] - The Guangfa Balanced Growth Mixed A Fund has achieved a year-to-date return of 50.18%, ranking 1148 out of 8154 in its category, and a one-year return of 48.28%, ranking 1193 out of 8046 [2] - The fund manager, Yang Dong, has been in position for 4 years and 123 days, with a total asset scale of 23.666 billion CNY and a best fund return of 103.21% during his tenure [2]
奥浦迈股价涨5.03%,广发基金旗下1只基金重仓,持有152.83万股浮盈赚取443.2万元